belantamab mafodotin anti-bcma adc
Published 5 years ago • 2.3K plays • Length 1:45Download video MP4
Download video MP3
Similar videos
-
6:42
dreamm-5 platform trial: belantamab mafodotin in combination with novel agents in patients with rrmm
-
1:51
an update on the use of belantamab mafodotin in multiple myeloma
-
5:38
dreamm-6: safety and tolerability of belantamab mafodotin in combination with bortezomib/dex in rrmm
-
6:39
dreamm-9: belantamab mafodotin standard care in newly diagnosed multiple myeloma
-
3:29
belantamab mafodotin in myeloma: advantages and disadvantages
-
2:24
what is the current status of belantamab and its potential reapproval?
-
1:04:12
a promising future for treating multiple myeloma with bispecific antibodies
-
3:59
dreamm-9: phase i study of belantamab mafodotin standard of care in pts w/transplant-ineligible ndmm
-
4:58
dreamm-2: single-agent belantamab mafodotin in patients with rrmm and renal impairment
-
1:33
the potential role of belantamab mafodotin in multiple myeloma
-
6:52
health-related quality of life in rrmm patients treated with ide-cel vs belantamab mafodotin
-
1:04
mechanism of action of belantamab mafodotin
-
1:58
dr. lonial on data with belantamab mafodotin in multiple myeloma
-
3:19
what is bcma
-
14:56
all about blenrep (belantamab mafodotin-blmf)
-
2:08
dr. richardson on preliminary data with belantamab mafodotin in multiple myeloma
-
3:00
results of a phase i study of belantamab mafodotin in combination with krd for treating myeloma
-
3:21
belantamab mafodotin for myeloma: phase 1 data & patient-reported outcomes
-
7:06
efficacy and safety of elranatamab bcma-cd3 bispecific antibody, in patients with rrmm